#### TRIHEXYPHENIDYL HYDROCHLORIDE - trihexyphenidyl hydrochloride tablet Novitium Pharma LLC


-----

Novitium Pharma LLC.

# **TRIHEXYPHENIDYL HYDROCHLORIDE Tablets, USP 2 mg and 5 mg Rx Only**

#### DESCRIPTION

Trihexyphenidyl hydrochloride Tablets, USP is a synthetic antispasmodic drug available in the following forms: Tablets, 2 mg and 5 mg. It is designated chemically 1-Piperidinepropanol, $\alpha$ -cyclohexyl- $\alpha$ -phenyl-, hydrochloride. The structural formula is represented below:



Trihexyphenidyl Hydrochloride Tablets, USP 2 mg and 5 mg contain the following inactive ingredients: Microcrystalline cellulose, magnesium stearate and sodium starch glycolate.

#### CLINICAL PHARMACOLOGY

Trihexyphenidyl Hydrochloride is the substituted piperidine salt, 3-(1-piperidyl)- 1-phenylcyclohexyl-1-propanol hydrochloride, which exerts a direct inhibitory effect upon the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly upon the muscle tissue itself and indirectly through an inhibitory effect upon the parasympathetic nervous system. Its therapeutic properties are similar to those of atropine, although undesirable side effects are ordinarily less frequent and severe than with the latter.

#### **INDICATIONS & USAGE**

This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.

#### WARNINGS

Patients to be treated with trihexyphenidyl hydrochloride should have a gonioscope evaluation and close monitoring of intraocular pressures at regular periodic intervals.

# PRECAUTIONS

# **GENERAL PRECAUTIONS**

Although trihexyphenidyl hydrochloride is not contraindicated for patients with cardiac, liver, or kidney disorders, or with hypertension, such patients should be maintained under close observation.

Since the use of trihexyphenidyl hydrochloride may, in some cases, continue indefinitely and since it has atropine- like properties, patients should be subjected to constant and careful long-term observation to avoid allergic and other untoward reactions. In as much as trihexyphenidyl hydrochloride possesses some parasympatholytic activity, it should be used with caution in patients with glaucoma, obstructive disease of the gastrointestinal or genitourinary tracts, and in elderly males with possible prostatic hypertrophy.

Geriatric patients, particularly over the age of 60, frequently develop increased sensitivity to the actions of drugs of this type, and hence, require strict dosage regulation. Incipient glaucoma may be precipitated by parasympatholytic drugs such as trihexyphenidyl hydrochloride.

Tardive dyskinesia may appear in some patients on long term therapy with antipsychotic drugs or may occur after therapy when these drugs have been discontinued. Antiparkinson agents do not alleviate the symptoms of tardive dyskinesia and in some instances may aggravate them. However, parkinsonism and tardive dyskinesia often coexist in patients receiving chronic neuroleptic treatment, and anticholinergic therapy with trihexyphenidyl hydrochloride may relieve some of these parkinsonism symptoms.

# **ADVERSE REACTIONS**

Minor side effects, such as dryness of the mouth, blurring of vision, dizziness, mild nausea, or nervousness, will be experienced by 30 to 50 percent of all patients. These sensations, however, are much less troublesome with trihexyphenidyl hydrochloride than with belladonna alkaloids and are usually less disturbing than unalleviated parkinsonism. Such reactions tend to become less pronounced, and even to disappear, as treatment continues. Even before these reactions have remitted spontaneously, they may often be controlled by careful adjustment of the dosage form, amount of drug, or interval between doses.

Isolated instances of suppurative parotitis secondary to excessive dryness of the mouth, skin rashes, dilatation of the colon, paralytic ileus, and certain psychiatric manifestations such as delusions and hallucinations, plus one doubtful case of paranoia all of which may occur with any of the atropine-like drugs, have been rarely reported with trihexyphenidyl hydrochloride.

Patients with arteriosclerosis or with a history of idiosyncrasy to other drugs may exhibit reactions of mental confusion, agitation, disturbed behavior, or nausea and vomiting. Such patients should be allowed to develop a tolerance through the initial administration of a small dose and gradual increase in dose until an effective level is reached. If a severe reaction should occur, administration of the drug should be discontinued for a few days and then resumed at a lower dosage. Psychiatric disturbances can result from indiscriminate use (leading to overdosage) to sustain continued euphoria.

Potential side effects associated with the use of any atropine-like drugs include constipation, drowsiness, urinary hesitancy or retention, tachycardia, dilation of the pupil, increased intraocular tension, weakness, vomiting, and headache.

The occurrence of angle-closure glaucoma due to long-term treatment with trihexyphenidyl hydrochloride has been reported.

#### To report SUSPECTED ADVERSE REACTIONS, contact Novitium Pharma LLC at 1-516-305-1658 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

# **DOSAGE & ADMINISTRATION**

Dosage should be individualized. The initial dose should be low and then increased gradually, especially in patients over 60 years of age. Whether trihexyphenidyl hydrochloride may best be given before or after meals should be determined by the way the patient reacts. Postencephalitic patients, who are usually more prone to excessive salivation, may prefer to take it after meals and may, in addition, require small amounts of atropine which, under such circumstances, is sometimes an effective adjuvant. If trihexyphenidyl hydrochloride tends to dry the mouth excessively, it may be better to take it before meals, unless it causes nausea. If taken after meals, the thirst sometimes induced can be allayed by mint candies, chewing gum or water.

# Trihexyphenidyl Hydrochloride in Idiopathic Parkinsonism

As initial therapy for parkinsonism, 1 mg may be administered the first day. The dose may then be increased by 2 mg increments at intervals of three to five days, until a total of 6 to 10 mg is given daily. The total daily dose will depend upon what is found to be the optimal level. Many patients derive maximum benefit from this daily total of 6 to 10 mg, but some patients, chiefly those in the postencephalitic group, may require a total daily dose of 12 to 15 mg.

# Trihexyphenidyl Hydrochloride in Drug-Induced Parkinsonism

The size and frequency of dose of trihexyphenidyl hydrochloride needed to control extrapyramidal reactions to commonly employed tranquilizers, notably the phenothiazines, thioxanthenes, and butyrophenones, must be determined empirically. The total daily dosage usually ranges between 5 and 15 mg, although, in some cases, these reactions have been satisfactorily controlled on as little as 1 mg daily. It may be advisable to commence therapy with a single 1 mg dose. If the extrapyramidal manifestations are not controlled in a few hours, the subsequent doses may be progressively increased until satisfactory control is achieved. Satisfactory control may sometimes be more rapidly achieved by temporarily reducing the dosage of the tranquilizer on instituting trihexyphenidyl hydrochloride therapy and then adjusting dosage of both drugs until the desired ataractic effect is retained without onset of extrapyramidal reactions.

It is sometimes possible to maintain the patient on a reduced trihexyphenidyl hydrochloride dosage after the reactions have remained under control for several days. Instances have been reported in which these reactions have remained in remission for long periods after trihexyphenidyl hydrochloride therapy was discontinued.

# Concomitant Use of Trihexyphenidyl Hydrochloride with Levodopa

When trihexyphenidyl hydrochloride is used concomitantly with levodopa, the usual dose of each may need to be reduced. Careful adjustment is necessary, depending on side effects and degree of symptom control. Trihexyphenidyl hydrochloride dosage of 3 to 6 mg daily, in divided doses, is usually adequate.

# Concomitant Use of Trihexyphenidyl Hydrochloride with Other Parasympathetic Inhibitors

Trihexyphenidyl Hydrochloride may be substituted, in whole or in part, for other parasympathetic inhibitors. The usual technique is partial substitution initially, with progressive reduction in the other medication as the dose of trihexyphenidyl hydrochloride is increased.

Trihexyphenidyl Hydrochloride Tablets - The total daily intake of trihexyphenidyl hydrochloride tablets is tolerated best if divided into 3 doses and taken at mealtimes. High doses (> 10 mg daily) may be divided into 4 parts, with 3 doses administered at meal times and the fourth at bedtime.

#### HOW SUPPLIED

Trihexyphenidyl Hydrochloride Tablets, USP 2 mg are available as white, flat face, beveled edge and round. The upper layer is bisected and debossed "212/N", the lower layer is plain:

Bottle of 100's NDC 70954-212-10 Bottle of 1000's NDC 70954-212-20

Trihexyphenidyl Hydrochloride Tablets, USP 5 mg are available as white, flat face, beveled edge and round. The upper layer is bisected and debossed "211/N", the lower layer is plain:

Bottle of 100's NDC 70954-211-10 Bottle of 1000's NDC 70954-211-20


Dispense in a tight container with child-resistant closure.

Store at 20° to 25° (68° to 77°F) [See USP Controlled Room Temperature].

Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey-08520

#### PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


Trihexyphenidyl Hydrochloride Tablets, USP 2 mg 100's



Trihexyphenidyl Hydrochloride Tablets, USP 2 mg 1000's

NDC 70954-212-20	Each Tablet Contains Trihexyphenidyl Hydrochloride, USP2 mg.		
Trihexyphenidyl Hydrochloride	Dispense in a tight container with child-resistance closure.	-	H
Tablets, USP	Dosage: See accompanying package insert for dosage and full prescribing information.	122	
2 mg	Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].	954 2	(ARI
Rx only	Manufactured by:	20	2
1000 Tablets	Novitium Pharma LLC 70 Lake Drive, East Windsor	zm	9
novitium	New Jersey 08520 Issued: 02/19 LB4146-01		_

#### Trihexyphenidyl Hydrochloride Tablets, USP 5 mg 100's



# Trihexyphenidyl Hydrochloride Tablets, USP 5 mg 1000's

NDC 70954-211-20	Each Tablet Contains Trihexyphenidyl Hydr USP5 mg.	rochloride,
Trihexyphenidyl Hydrochloride	Dispense in a tight container with child-res closure.	sistance
Tablets, USP	Dosage: See accompanying package inse dosage and full prescribing information.	t for
5 mg	Store at 20°C to 25°C (68°F to 77°F) [See Controlled Room Temperature].	
Rx only	Manufactured by:	2°
1000 Tablets	Novitium Pharma LLC 70 Lake Drive, East Windsor New Jersey 08520	zm Z
novitium		147-01

TRIHEXYPHENIDYL HYDROCHLORIDE trihexyphenidyl hydrochloride tablet				
Product Information				
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70954-211	
Route of Administration	ORAL			

TRIHEX YPHENDYL HYDRO CHLO RIDE (UNE A06 IC82577) (TRIHEX YPHENDYL - TRIHEX YPHENDYL MYDRO CHLO RIDE S 5 mg Inactive Ingredients Ingredi		Ingredient Name Basis of Streng					rength	Strengt
Ingredient Name     Strength       MICROCRYSTALLINE CELLULOSE (UNR: OPIR32D61U)       MAGNESIUM STEARATE (UNR: 70097MGB0)	TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: AO61G82577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL					L -		
MICRO CRYSTALLINE CELLULOSE (UNII: OPIR32D61U) MAGNESIUM STARATE (UNII: 70097/M6120) SODUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856/J3G2A2) Product Characteristics Color WHITE Score 2 pieces Shape ROUND Size 100mm Flavor 21LN Packaging # Item Code Package Description Marketing Start Date Marketing End Dat 1 NDC:70954-211-10 100 in 1 BOTTLE; Type 0: Not a Combination Product 0/28/2019 1 NDC:70954-211-20 1000 in 1 BOTTLE; Type 0: Not a Combination Product 0/28/2019 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Dat ANDA ANDA 040254 0120 19 FIRIHEXYPHENIDYL HYDROCHLORIDE The Score 0000 Firit Content of the Scor	Inactive Ingredie	ents						
MAGNESIUM STEARATE (UNII: 70097/M6180)       SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)       SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)         Product Characteristics       Score       2 pieces         Shape       ROUND       Size       Iomm         Shape       ROUND       Size       Iomm         Flavor       Imprint Code       211;N       211;N         Packaging         #       Item Code       Package Description       Marketing Start Date       Marketing Laboration         1 NOC:70954-211-10       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019       Marketing Laboration       Marketing Start Date       Marketing Laboration       Marketing Start Date       Marketing Laboration       Marketing Start Date       Marketing Laboration       Marketing Laboration <td></td> <td></td> <td>Ingredien</td> <td>it Name</td> <td></td> <td></td> <td></td> <td>Strength</td>			Ingredien	it Name				Strength
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNE: 5056/3G2A2)  Product Characteristics  Color WHTE Score 2 jeccs  Shape A ROUND Size 10mm  Flavor 21J,N  Contains I Package Description Imprint Code 21J,N  Packaging  f Item Code Package Description Marketing Start Date Marketing End Dat  1 NDC:70954-211-0 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/28/2019  VAC:70954-211-20 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/28/2019  VAC:70954-211-20 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/28/2019  VAREE ting Information  Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Dat ANDA ANDA04025  FTRIHEXYPHENDYL HYDROCHLORUS  Freibexyphenidyl hydrochloride tablet  Froduct Information  Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:70954-212 Route of Administration ORAL  Ingredient Name Ingredie	MICROCRYSTALLIN	NE CELLUI	L <b>OSE</b> (UNII: OP1R32D61U	)				
WIRTE       Score       2 pieces         Shape       ROUND       Size       IDum       2         Flavor       Imprint Code       211/N         Contains       Imprint Code       211/N         Packaging         #       Item Code       Packaging         #       Item Code       Package Description       Marketing Start Date       Marketing Info         NDC:70954-211-20       IOO0 in 1 BOTTLE; Type 0: Not a Combination Product       0.128/2019         Marketing Information       Marketing Start Date       Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Dat         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Dat         NDA       ANDA040254       OI28/2019       VERTHEXTPENT         Product Information       Item Code (Source)       NDC:70954-212         Raute of Administration       ORAI.         ORAI.       VERTHEXTPENT         Ingredient Name	MAGNESIUM STEAR	ATE (UNII:	70097M6I30)					
Color       WHTFE       Score       2 pieces         Shape       ROUND       Size       10mm         Flavor       Imprint Code       211,N         Contains       Imprint Code       211,N         Packaging       Imprint Code       211,N         Packaging       Imprint Code       211,N         Packaging       Imprint Code       212,2019         Packaging       01/28/2019       01/28/2019         NDC:70954-211-20       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019         NDC:70954-211-20       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019         Marketing Start Date       Marketing Start Date       Marketing End Date         ANDA 040254       01/28/2019       Marketing End Date         Product Information       ANDA 040254       01/28/2019       Marketing End Date         Firehyphenidyl hydrochloride tablet       NDC:70954-212       NDC:70954-212         Product Type       HUMAN PRESCRIPTION DRUG       Item Code (Source)       NDC:70954-212         Route of Administration       ORAL       Item Code (Source)       NDC:70954-212         Active Ingredient/Active Koiety       Ingredient Name       Item Soi Streng       Streng         Ingredient Name	SO DIUM STARCH GI	LYCOLAT	E TYPE A POTATO (UNI	I: 5856J3G2A2)				
Color       WHTFE       Score       2 pieces         Shape       ROUND       Size       10mm         Flavor       Imprint Code       211,N         Contains       Imprint Code       211,N         Packaging       Imprint Code       211,N         Packaging       Imprint Code       211,N         Packaging       Imprint Code       212,2019         Packaging       01/28/2019       01/28/2019         NDC:70954-211-20       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019         NDC:70954-211-20       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019         Marketing Start Date       Marketing Start Date       Marketing End Date         ANDA 040254       01/28/2019       Marketing End Date         Product Information       ANDA 040254       01/28/2019       Marketing End Date         Firehyphenidyl hydrochloride tablet       NDC:70954-212       NDC:70954-212         Product Type       HUMAN PRESCRIPTION DRUG       Item Code (Source)       NDC:70954-212         Route of Administration       ORAL       Item Code (Source)       NDC:70954-212         Active Ingredient/Active Koiety       Ingredient Name       Item Soi Streng       Streng         Ingredient Name	Product Charact	eristics						
Shape       ROUND       Size       Inmint Code       Inmint Code       211,3         Flavor       Imprint Code       211,3       Imprint Code       211,3         Contains       Imprint Code       211,3       Imprint Code       211,3         Packaging       Imprint Code       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019       Marketing Start Date       Marketing Tat Date       Marketing Info         I NDC:70954-211-10       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019       Marketing Start Date       Marketing Info         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         NDA       ANDA040254       01/28/20 19       Marketing Start Date       Marketing End Date         NDA       ANDA040254       01/28/20 19       Marketing Start Date       Marketing End Date         NDA       ANDA040254       01/28/20 19       Marketing Start Date       Marketing End Date         Start Product Information       HUMAN PRESCRIPTION DRUG       Item Code (Source)       MC:70954-212         Route of Administration       ORAL       Marketing Start S			WHITE	Score			2 pieces	
Paver marketing Category Application Number or Monograph Citation Marketing Start Date ANDA040254 ANDA055 ANDA055 ANDA055 ANDA055 ANDA055 ANDA0555 ANDA05555 ANDA05555 ANDA05555 ANDA05555 ANDA05555 ANDA05555 ANDA055555 ANDA055555 ANDA055555 ANDA055555 ANDA055555555 ANDA0555555 ANDA055555555 ANDA055555555555555555555555555555555555							-	
Contains         Packaging         #       Item Code       Package Description       Marketing Start Date       Marketing Start Date       Marketing Start Date       Marketing Start Date       Marketing Information         Marketing Information       Marketing Start Date       Marketing Start Date       Marketing End Date         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         ANDA       ANDA040254       01/28/2019       01/28/2019       Marketing End Date         FRIHEXYPHENIDYL HYDROCHLORIDE       Frihexyphenidyl hydrochloride tablet       Marketing Cole (Source)       NDC:70954-212         Product Information       QRAL       Item Code (Source)       NDC:70954-212       NDC:70954-212         Active Ingredient/Active Molety       Ingredient Name       Basis of Strength       Streng         TRIHEXYPHENDYL HYDROCHLORIDE (UNIE AOG IG82577) (TRIHEXYPHENIDYL       TRIHEXYPHENIDYL       2 mg								
Packaging           Marketing Start Date         Marketing End Date           1         NDC:70954-211-10         100 in 1 BOTTLE; Type 0: Not a Combination Product         0/28/2019           2         NDC:70954-211-20         1000 in 1 BOTTLE; Type 0: Not a Combination Product         0/28/2019           Marketing Information         Marketing Start Date         Marketing End Date           Marketing Category         Application Number or Monograph Citation         Marketing Start Date         Marketing End Date           NDA         ANDA040254         0/28/2019         0/28/2019         Marketing End Date				mprint cout			, . ,	
Item Code       Package Description       Marketing Start Date       Marketing End Date         1       NDC:70954-211-10       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019       01/28/2019         2       NDC:70954-211-20       1000 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019       01/28/2019         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         ANDA       ANDA040254       01/28/2019       01/28/2019       Marketing End Date         FRIHEXYPHENIDYL HYDROCHLORIDE       NDC:70954-212       NDC:70954-212       NDC:70954-212         Product Information       NDC:70954-212       NDC:70954-212       NDC:70954-212         Route of Administration       ORAL       NDC:70954-212       NDC:70954-212         Active Ingredient/Active Moiety       Ingredient Name       Basis of Strength       Streng         Ingredient Name       Basis of Strength       Streng       Streng         InflexyPhenIDYL HYDROCHLORIDE (UNI: A06 IG82577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL       7 ma								
Item Code       Package Description       Marketing Start Date       Marketing End Date         1 NDC:70954-211-10       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019       01/28/2019         2 NDC:70954-211-20       1000 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019       01/28/2019         Marketing Information       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         ANDA       Application Number or Monograph Citation       01/28/2019       Marketing End Date         FRIHEXYPHENTDYL       HYDROCHLORIDE       01/28/2019       Marketing End Date         Product Information       Marketing Start Date       Marketing End Date         Anda of Administration       ORAL       NDC:70954-212         Active Ingredient/Active Moiety       Ingredient Name       Basis of Strength       Streng         TRIHEXYPHENIDYL HYDROCHLORIDE (UNI: A06 IG82577) (TRIHEXYPHENIDYL - TRIHEXYPHENIDYL - TRIHEXYPHENIDYL - TRIHEXYPHENIDYL       TRIHEXYPHENIDYL       7 ma	Packaging							
1 NDC:70954-211-10       100 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019         2 NDC:70954-211-20       1000 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019         Marketing Information         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         ANDA       ANDA040254       01/28/2019       Marketing End Date         FRIHEXYPHENIDYL HYDROCHLORIDE         rihexyphenidyl hydrochloride tablet         Product Information         Product Type       HUMAN PRESCRIPTION DRUG       Item Code (Source)       NDC:70954-212         Route of Administration       ORAL         Active Ingredient/Active Moiety         Ingredient Name       Basis of Strength       Streng         TRIHEXYPHENIDYL HYDROCHLORIDE (UNI: A06 IG82577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL       2 ma			Package Descrip	tion	Mark	eting Start Date	Marketi	ng End Dat
2 NDC:70954-211-20       1000 in 1 BOTTLE; Type 0: Not a Combination Product       01/28/2019         Marketing Information         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         ANDA       ANDA040254       01/28/2019       Marketing End Date         Interview of Administration         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         Interview of Administration       Marketing Start Date       Marketing End Date         Interview of Administration       Marketing Start Date       Marketing End Date         Active Ingredient/Active Moiety         Ingredient Name       Basis of Strength       Streng         TRIHEXYPHENIDYL HYDROCHLORIDE         Ingredient Name       Basis of Strength       Streng		100 in 1 B				-		0
Marketing Information       Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         ANDA       ANDA040254       0 1/28/20 19       0 1/28/20 19       Narketing End Date         FRIHEXYPHENIDYL HYDROCHLORIDE         ride xapple colspan="3">Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         FRIHEXYPHENIDYL HYDROCHLORIDE         Fridexyphenidyl hydrochloride tablet         Product Information         Product Type       HUMAN PRESCRIPTION DRUG       Item Code (Source)       NDC:70954-212         Route of Administration       ORAL         Active Ingredient/Active Moiety         Ingredient Name       Basis of Strength       Streng         TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: AO6 1682577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL					01/28/2	0 19		
Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing End Date         ANDA       ANDA040254       01/28/2019       01/28/2019       01/28/2019         FRIHEXYPHENDYL HYDROCHLORIDE         FRIHEXYPHENDYL HYDROCHLORIDE         Intervention of table of ta	Markoting Inf	formati	0.11					
ANDA ANDA040254 01/28/219 TRIHEXYPHENIDYL VIYL UVUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU				nogranh Citation	Mark	eting Start Date	Marketi	ng End Date
TRIHEXYPHENIDYL HYDROCHLORIDE         rihexyphenidyl hydrochloride tablet         Product Information         Product Type       HUMAN PRESCRIPTION DRUG       Item Code (Source)       NDC:70954-212         Route of Administration       ORAL       NDC:70954-212         Active Ingredient/Active Moiety       Item Code (Source)       NDC:70954-212         Route of Ingredient/Active Moiety       Strength       Strength         Ingredient Name       Basis of Strength       Strength         TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: A061G82577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL       2 mg	Marketing Cutegor			logruph chuton			iviui ke u	
rihexyphenidyl hydrochloride table:          Product Information       Item Jee (Source)       NDC:70 > 54 - 212         Product Type       HUMAN PRESCRIPTION DRUG       Item Jee (Source)       NDC:70 > 54 - 212         Route of Administration       ORAL       Vertex State       State       State         Active Ingredient/Active Moiety         Ingredient Name       Basis of Streth       Streng         TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: A061G82577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL       2 mg	ANDA	11110/10	40254		01/20/2	.015		
rihexyphenidyl hydrochloride table:          Product Information       Item Jet (Source)       NDC:70 > 54 - 212         Product Type       HUMAN PRESCRIPTION DRUG       Item Jet (Source)       NDC:70 > 54 - 212         Route of Administration       ORAL       Version (Source)       NDC:70 > 54 - 212         Active Ingredient/Active Moiety       Item Jet (Source)       NDC:70 > 54 - 212         Ingredient/Active Moiety       Streng         TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: A061G82577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL       2 mg	ANDA							
Product Type       HUMAN PRESCRIPTION DRUG       Item Code (Source)       NDC:70954-212         Route of Administration       ORAL <t< th=""><th>ANDA</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>	ANDA							
Route of Administration       ORAL         Active Ingredient/Active Moiety       Strength         Ingredient Name       Basis of Strength       Strength         TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: A061G82577) (TRIHEXYPHENIDYL -       TRIHEXYPHENIDYL       TRIHEXYPHENIDYL       2 mg	FRIHEXYPHI			ORIDE				
Active Ingredient/Active Moiety Ingredient Name Basis of Strength Streng TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: AO6 1G8 2577) (TRIHEXYPHENIDYL - TRIHEXYPHENIDYL 2 mg	<b>FRIHEXYPHI</b> rihexyphenidyl hydi	rochloride		DRIDE				
Ingredient Name     Basis of Strength     Streng       TRIHEXYPHENIDYL HYDROCHLORIDE (UNII: A061G82577) (TRIHEXYPHENIDYL -     TRIHEXYPHENIDYL     2 mg	<b>FRIHEXYPHI</b> rihexyphenidyl hydr <b>Product Informa</b>	rochloride	tablet		Item (	Code (Source)	NDC:7	0954-212
<b>TRIHEXYPHENIDYL HYDROCHLORIDE</b> (UNII: AO61G82577) (TRIHEXYPHENIDYL - TRIHEXYPHENIDYL 2 mg	<b>FRIHEXYPHI</b> rihexyphenidyl hydı <b>Product Informa</b> <b>Product Type</b>	rochloride I <b>tion</b>	tablet HUMAN PRESCRIP		Ite m (	Code (Source)	NDC:7	0954-212
	<b>FRIHEXYPHI</b> rihexyphenidyl hydr <b>Product Informa</b> Product Type Route of Administra	rochloride a <b>tion</b> ation	tablet HUMAN PRESCRIP ORAL		Item(	Code (Source)	NDC:7	0954-212
	<b>FRIHEXYPHI</b> rihexyphenidyl hydr <b>Product Informa</b> Product Type Route of Administra	ochloride tion ation tt/Active	tablet HUMAN PRESCRIE ORAL		Ite m (			0954-212 Strengt

		Ingred	ient Name		Strength	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)						
MAGNESIUM STEARATE (UNII: 70097M6I30)						
SODIUM STARCH GI	YCOLAT	Γ <b>Ε ΤΥΡΕ Α ΡΟΤΑΤΟ</b> (U	JNII: 5856J3G2A2)			
Product Charact	eristics					
Color		WHITE	Score		2 pieces	
Shape		ROUND	Size		8 mm	
Flavor			Imprint Code		212;N	
Contains						
Packaging						
# Item Code		Package Description		Marketing Start Date	Marketing End Date	
1 NDC:70954-212-10	10 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/28/2019					
<b>2</b> NDC:70954-212-20	OC:70954-212-20 1000 in 1 BOTTLE; Type 0: Not a Combination Product		0 1/28/20 19			
Marketing Information						
Marketing Categor	у Арр	olication Number or Monograph Citation		Marketing Start Date	Marketing End Date	
ANDA	ANDA	040254		0 1/28/20 19		

# Labeler - Novitium Pharma LLC (080301870)

Establishment			
Name	Address	<b>ID/FEI</b>	Business Operations
Novitium Pharma LLC		080301870	MANUFACTURE(70954-211, 70954-212), PACK(70954-211, 70954-212)

Revised: 1/2019

Novitium Pharma LLC